购物车
- 全部删除
- 您的购物车当前为空
NS13001 (N-(4-Chlorophenyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-9-methyl-9H-purin-6-amine) 是口服有效的 SK 通道选择性正向变构调节剂。NS13001 对 SK2 和 SK3 通道的 EC50分别为 1.8 μM 和 0.14 μM。NS13001 在脊髓小脑共济失调 2 型和其他小脑共济失调方面具有研究价值。
为众多的药物研发团队赋能,
让新药发现更简单!
NS13001 (N-(4-Chlorophenyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-9-methyl-9H-purin-6-amine) 是口服有效的 SK 通道选择性正向变构调节剂。NS13001 对 SK2 和 SK3 通道的 EC50分别为 1.8 μM 和 0.14 μM。NS13001 在脊髓小脑共济失调 2 型和其他小脑共济失调方面具有研究价值。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 289 | 现货 | |
5 mg | ¥ 993 | 现货 | |
10 mg | ¥ 1,820 | 现货 | |
25 mg | ¥ 3,230 | 现货 | |
50 mg | ¥ 4,560 | 现货 | |
100 mg | ¥ 6,390 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 1,090 | 现货 |
产品描述 | NS13001 (N-(4-Chlorophenyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-9-methyl-9H-purin-6-amine) is a potent, selective, orally active allosteric positive modulator of SK channels (small conductance calcium-activated potassium channels). The EC50s are 1.8 and 0.14 μM for SK2 and SK3, respectively. NS13001 holds promise as a potential therapeutic agent for treatment of spinocerebellar ataxia type 2 (SCA2) and possibly other cerebellar ataxias. |
靶点活性 | SK3:0.14 μM(EC50), SK2:(EC50)1.8 μM |
别名 | N-(4-chlorophenyl)-2-(3,5-dimethylpyrazol-1-yl)-9-methylpurin-6-amine, N-(4-Chlorophenyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-9-methyl-9H-purin-6-amine |
分子量 | 353.81 |
分子式 | C17H16ClN7 |
CAS No. | 1063331-94-1 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 90 mg/mL (254.37 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.